Somu Subramaniam is the co-founder and Managing Partner of New Science Ventures. Somu serves on the Board of Directors of Achronix Semiconductor Corporation, Silicon Space Technology, Dali Wireless, Oxyrane, Juventas Therapeutics, Resolve Therapeutics, Dezima Pharma, Vaultive, TigerText and iCAD. Somu has also served on the Boards of Ception (sold to Cephalon), BioVex (sold to Amgen), Lightwire (sold to Cisco) and K2M (sold to Welsh Carson). Prior to founding NSV, Somu was a Director of McKinsey & Co. and at various times led their Strategy practice, Technology practice and HealthCare practice. He was also a member of McKinsey’s Investment Committee. Somu received his undergraduate degree (B.Tech.) from the Indian Institute of Technology and his M.B.A. from Harvard Business School.